ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product
ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product Fundamental Analysis
ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product (7331.HK) shows weak financial fundamentals with a PE ratio of N/A, profit margin of 0.00%, and ROE of 0.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 25.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 7331.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak7331.HK struggles to generate sufficient returns from assets.
Valuation Score
Weak7331.HK trades at a premium to fair value.
Growth Score
Weak7331.HK faces weak or negative growth trends.
Financial Health Score
Moderate7331.HK shows balanced financial health with some risks.
Profitability Score
Weak7331.HK struggles to sustain strong margins.
Key Financial Metrics
Is 7331.HK Expensive or Cheap?
Debt/Equity
ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product has a debt-to-equity ratio of 0.00, indicating its leverage.
How Well Does 7331.HK Make Money?
Net Profit Margin
For every $100 in sales, ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.00 in profit for every $100 of shareholder equity.
ROA
ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
N/A
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
N/A
vs 25 benchmark
P/B Ratio
Price to book value ratio
N/A
vs 25 benchmark
P/S Ratio
Price to sales ratio
N/A
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.00
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How 7331.HK Stacks Against Its Sector Peers
| Metric | 7331.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | N/A | 18.66 | N/A |
| ROE | 0.00% | 804.00% | Weak |
| Net Margin | 0.00% | 2258.00% | Weak |
| Debt/Equity | 0.00 | 1.03 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 662.03 | Weak Liquidity |
| ROA | 0.00% | -24049.00% (disorted) | Weak |
7331.HK outperforms its industry in 1 out of 5 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews ChinaAMC Direxion NASDAQ-100 Daily (-1x) Inverse Product's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical